ADVANCED MELANOMA
Clinical trials for ADVANCED MELANOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED MELANOMA trials appear
Sign up with your email to follow new studies for ADVANCED MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell therapy shows promise for advanced melanoma in early trial
Disease control OngoingThis early-phase trial tests a new combination treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) grown in the lab and given back along with a drug called ANV4…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated May 17, 2026 08:02 UTC
-
Could a drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF to the immunotherapy ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if the combination improved …
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:58 UTC
-
New combo therapy gives hope to melanoma patients who failed standard treatment
Disease control OngoingThis study tests whether combining two immunotherapy drugs—T-VEC (a virus-based therapy injected into tumors) and pembrolizumab (an antibody given by IV)—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 43 adults with sta…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Melanoma patients may get a break from therapy thanks to PET scans
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. Using PET/CT scans and tumor biopsies as guides, the goal is to see if stopping treatment sooner still keeps the cancer u…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for tough melanoma: experimental drug targets resistant tumors
Disease control OngoingThis study tests a new drug called botensilimab, alone or with another drug, in 150 adults with advanced melanoma that no longer responds to standard immunotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants must have had prior anti…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New triple therapy aims to boost immune attack on tough cancers
Disease control OngoingThis early-phase study tests whether adding an experimental drug (APX005M) to two standard immunotherapies is safe and tolerable for people with advanced melanoma or kidney cancer. About 26 adults who have not had prior immune therapy for their advanced disease will receive the c…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Last-Resort combo for advanced melanoma now available through expanded access
Disease control NO_LONGER_AVAILABLEThis program provides early access to a combination of VO (vusolimogene oderparepvec) and nivolumab for adults with advanced melanoma that has worsened after anti-PD-1 treatment. The goal is to offer a potential treatment option while collecting real-world data. Participants must…
Matched conditions: ADVANCED MELANOMA
Sponsor: Replimune, Inc. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC